Qunyong Peng , Tianqi Ma , Lingfang He , Xunjie Cheng , Wei Xie
{"title":"Dose-response associations of accelerometer-measured physical activity with mortality across frailty levels: A prospective cohort study","authors":"Qunyong Peng , Tianqi Ma , Lingfang He , Xunjie Cheng , Wei Xie","doi":"10.1016/j.exger.2025.112858","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Limited evidence, majorly based on questionnaire-derived measurements, was available to reflect long-term benefits of physical activity (PA) across different frailty levels.</div></div><div><h3>Methods</h3><div>We included 81,219 UK Biobank participants (mean age 61.88 years; 41.2 % men) with accelerometer data. Participants were categorized using frailty phenotype as robust, prefrail, and frail. Restricted cubic splines described the associations of continuous light intensity PA (LPA), moderate/vigorous intensity PA (MVPA), and total PA (TPA) levels with all-cause mortality. Adjusted hazard ratios (HRs) of outcomes by multi-categorical LPA and MVPA levels were estimated. Further joint analyses were performed if significant interaction existed between PAs and frailty.</div></div><div><h3>Results</h3><div>Of the included participants, 54,081 (66.6 %) were robust and 1071 (1.3 %) were frail. Over a median follow-up of 10.68 years, 3825 (4.7 %) deaths occurred. For all-cause mortality, L-shaped nonlinear associations existed for LPA, MVPA, and TPA. Compared with <150 min/week, MVPA of 150–300, 300–600, and ≥600 min/week-related HRs were 0.57 (0.48–0.68), 0.39 (0.33–0.46), and 0.30 (0.25–0.36) for robust and 0.37 (0.23–0.58), 0.32 (0.20–0.53), and 0.18 (0.07–0.48) for frail people, respectively. MVPA-related associations were modified by frailty (<em>P</em><sub><em>interaction</em></sub> = 0.007). In joint analyses, compared with robust people with highest MVPA level, frail patients with MVPA <150 min/week had ~6 times higher risk of mortality, while those with frailty but MVPA ≥150 min/week had a relatively lower mortality risk than robust people with MVPA <150 min/week.</div></div><div><h3>Conclusion</h3><div>Dose-response associations existed between device-measured PA levels and mortality risk across different frailty levels. Frail patients benefited greater via MVPA engagement, which partially attenuated frailty-related excessive risk.</div></div>","PeriodicalId":94003,"journal":{"name":"Experimental gerontology","volume":"210 ","pages":"Article 112858"},"PeriodicalIF":4.3000,"publicationDate":"2025-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Experimental gerontology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0531556525001871","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Limited evidence, majorly based on questionnaire-derived measurements, was available to reflect long-term benefits of physical activity (PA) across different frailty levels.
Methods
We included 81,219 UK Biobank participants (mean age 61.88 years; 41.2 % men) with accelerometer data. Participants were categorized using frailty phenotype as robust, prefrail, and frail. Restricted cubic splines described the associations of continuous light intensity PA (LPA), moderate/vigorous intensity PA (MVPA), and total PA (TPA) levels with all-cause mortality. Adjusted hazard ratios (HRs) of outcomes by multi-categorical LPA and MVPA levels were estimated. Further joint analyses were performed if significant interaction existed between PAs and frailty.
Results
Of the included participants, 54,081 (66.6 %) were robust and 1071 (1.3 %) were frail. Over a median follow-up of 10.68 years, 3825 (4.7 %) deaths occurred. For all-cause mortality, L-shaped nonlinear associations existed for LPA, MVPA, and TPA. Compared with <150 min/week, MVPA of 150–300, 300–600, and ≥600 min/week-related HRs were 0.57 (0.48–0.68), 0.39 (0.33–0.46), and 0.30 (0.25–0.36) for robust and 0.37 (0.23–0.58), 0.32 (0.20–0.53), and 0.18 (0.07–0.48) for frail people, respectively. MVPA-related associations were modified by frailty (Pinteraction = 0.007). In joint analyses, compared with robust people with highest MVPA level, frail patients with MVPA <150 min/week had ~6 times higher risk of mortality, while those with frailty but MVPA ≥150 min/week had a relatively lower mortality risk than robust people with MVPA <150 min/week.
Conclusion
Dose-response associations existed between device-measured PA levels and mortality risk across different frailty levels. Frail patients benefited greater via MVPA engagement, which partially attenuated frailty-related excessive risk.